UPDATE: Acendiant Capital Initiates Cytori Therapeutics at Buy; Regenerative Medicine Pure Play

Acendiant Capital initiated coverage on Cytori Therapeutics CYTX with a Buy rating and a $3.25 price target. Acendiant Capital commented, "We believe that Cytori is an intriguing pure play regenerative medicine company. The Company's key product, the Celution System, facilitates the use of a cocktail of autologous, adipose-derived stem and regenerative cells (ADRCs) to treat cardiovascular disease and soft tissue defects. Thus far, the therapy has been evaluated in more than 40 investigator and Company sponsored studies and administered to over 5,000 patients." Cytori Therapeutics closed at $2.70 on Tuesday.